JP2006500422A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006500422A5 JP2006500422A5 JP2004539399A JP2004539399A JP2006500422A5 JP 2006500422 A5 JP2006500422 A5 JP 2006500422A5 JP 2004539399 A JP2004539399 A JP 2004539399A JP 2004539399 A JP2004539399 A JP 2004539399A JP 2006500422 A5 JP2006500422 A5 JP 2006500422A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- aminophenoxy
- ethane
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052757 nitrogen Inorganic materials 0.000 claims 50
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- PSDFQEVOCCOOET-UHFFFAOYSA-N 2-[2-(2-aminophenoxy)ethoxy]aniline Chemical compound NC1=CC=CC=C1OCCOC1=CC=CC=C1N PSDFQEVOCCOOET-UHFFFAOYSA-N 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 9
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 7
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 102000007590 Calpain Human genes 0.000 claims 5
- 108010032088 Calpain Proteins 0.000 claims 5
- 102000035195 Peptidases Human genes 0.000 claims 5
- 108091005804 Peptidases Proteins 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- -1 2-dodecyloxyethoxy Chemical group 0.000 claims 4
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- 208000025966 Neurological disease Diseases 0.000 claims 4
- 239000004365 Protease Substances 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 235000019419 proteases Nutrition 0.000 claims 4
- HHKRKUHUUKNPAJ-UHFFFAOYSA-N 2-phenylmethoxyethyl acetate Chemical compound CC(=O)OCCOCC1=CC=CC=C1 HHKRKUHUUKNPAJ-UHFFFAOYSA-N 0.000 claims 3
- 208000032843 Hemorrhage Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 208000034158 bleeding Diseases 0.000 claims 3
- 230000000740 bleeding effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000004968 inflammatory condition Effects 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 230000008733 trauma Effects 0.000 claims 3
- DCGAMMUAYLACBD-UHFFFAOYSA-N 2-dodecoxyethyl acetate Chemical compound CCCCCCCCCCCCOCCOC(C)=O DCGAMMUAYLACBD-UHFFFAOYSA-N 0.000 claims 2
- NXUORJNOBDRLQD-UHFFFAOYSA-N 2-octadecoxyethyl acetate Chemical compound CCCCCCCCCCCCCCCCCCOCCOC(=O)C NXUORJNOBDRLQD-UHFFFAOYSA-N 0.000 claims 2
- DTRWQAMXAFVMGD-UHFFFAOYSA-N 2-octoxyethyl acetate Chemical compound CCCCCCCCOCCOC(C)=O DTRWQAMXAFVMGD-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000026072 Motor neurone disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000025747 Rheumatic disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 230000001146 hypoxic effect Effects 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 230000004792 oxidative damage Effects 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000000451 tissue damage Effects 0.000 claims 2
- 231100000827 tissue damage Toxicity 0.000 claims 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 235000006481 Colocasia esculenta Nutrition 0.000 claims 1
- 240000004270 Colocasia esculenta var. antiquorum Species 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000002367 Retinal Perforations Diseases 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038897 Retinal tear Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010044696 Tropical spastic paresis Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000944 nerve tissue Anatomy 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000004264 retinal detachment Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims 1
- 208000006961 tropical spastic paraparesis Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL15192102A IL151921A0 (en) | 2002-09-25 | 2002-09-25 | Liphopilic diesters of chelating agent for inhibition of enzyme activity |
| PCT/IL2003/000225 WO2004028443A2 (en) | 2002-09-25 | 2003-03-16 | Lipophilic diesters of chelating agent for inhibition of enzyme activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006500422A JP2006500422A (ja) | 2006-01-05 |
| JP2006500422A5 true JP2006500422A5 (https=) | 2006-04-06 |
Family
ID=29596515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004539399A Pending JP2006500422A (ja) | 2002-09-25 | 2003-03-16 | 酵素活性を阻害するためのキレート化剤の親油性ジエステル |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7799831B2 (https=) |
| EP (1) | EP1546085B1 (https=) |
| JP (1) | JP2006500422A (https=) |
| AU (1) | AU2003214610C1 (https=) |
| CA (1) | CA2498420C (https=) |
| IL (2) | IL151921A0 (https=) |
| WO (1) | WO2004028443A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0508412D0 (en) * | 2005-04-26 | 2005-06-01 | Aq & Plc | Compositions for intestinal conditions |
| US9415032B2 (en) | 2011-10-05 | 2016-08-16 | The Johns Hopkins University | Membrane activated chelators and use in the prevention and treatment of parasitic infection |
| CN103373957A (zh) * | 2012-04-12 | 2013-10-30 | 成都苑东药业有限公司 | 一种具有神经细胞保护作用的螯合物 |
| US20150196625A9 (en) | 2013-01-07 | 2015-07-16 | Rudolph D. Paladini | Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof |
| WO2018236221A2 (en) * | 2017-06-03 | 2018-12-27 | Can Holding B.V. | Neurodegenerative peptide deposit dissolution |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6413949B1 (en) * | 1995-06-07 | 2002-07-02 | D-Pharm, Ltd. | Prodrugs with enhanced penetration into cells |
| AU2829395A (en) | 1994-06-16 | 1996-01-05 | Allergan, Inc. | Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators |
| WO1997009976A2 (en) * | 1995-09-01 | 1997-03-20 | Washington University | Method of reducing neurotoxic injury with zinc chelators |
| IL121844A0 (en) | 1997-09-28 | 1998-02-22 | Dpharm Ltd | Lipophilic diesters of chelating agents |
| WO2002047674A2 (en) | 2000-11-08 | 2002-06-20 | Thomas Jefferson University | Use of intracellular calcium chelators (e.g bapta-am) to increase surfactant secretion in the lungs |
-
2002
- 2002-09-25 IL IL15192102A patent/IL151921A0/xx unknown
-
2003
- 2003-03-16 CA CA2498420A patent/CA2498420C/en not_active Expired - Fee Related
- 2003-03-16 JP JP2004539399A patent/JP2006500422A/ja active Pending
- 2003-03-16 EP EP03710190A patent/EP1546085B1/en not_active Expired - Lifetime
- 2003-03-16 US US10/529,028 patent/US7799831B2/en not_active Expired - Lifetime
- 2003-03-16 WO PCT/IL2003/000225 patent/WO2004028443A2/en not_active Ceased
- 2003-03-16 AU AU2003214610A patent/AU2003214610C1/en not_active Ceased
-
2005
- 2005-03-13 IL IL167406A patent/IL167406A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI430796B (zh) | 端粒酶活化化合物及其使用方法 | |
| US20160051532A1 (en) | Method of Treating Cancer | |
| JP6261011B2 (ja) | 眼疾患処置薬 | |
| JP2003534312A (ja) | 薬剤として有用な環状アミノ酸誘導体 | |
| JP2022551270A (ja) | ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 | |
| JP2010516702A5 (https=) | ||
| AU2019362389A1 (en) | Compounds containing deuterium | |
| JP2012107073A (ja) | 眼の疾患、ならびに増殖および脈管形成応答に関連する疾患の処置に関する５，６，７−トリヒドロキシヘプタン酸およびアナログ | |
| JP2023520462A (ja) | フリードライヒ運動失調症を含むミトコンドリア病の予防および／または治療のための組成物および方法 | |
| JP2003528842A (ja) | 治療化合物としての置換カルコン | |
| JP2006500422A5 (https=) | ||
| JP6959246B2 (ja) | 治療に有効な量のジカルボン酸化合物を使用した、病気の予防、治療及び治癒 | |
| AU2022244467A1 (en) | 1,3-substituted cyclobutyl derivatives and uses thereof | |
| CN1141940C (zh) | 多环噻唑体系用于制备预防或治疗肥胖的药物的用途 | |
| CN106458938A (zh) | 手性2,5‑二取代的环戊烷甲酸衍生物及其用途 | |
| US20210107860A1 (en) | Nitroalkene non steroidal anti-inflammatory drugs (na-nsaids) and methods of treating inflammation related conditions | |
| US20250011293A1 (en) | Leukotriene synthesis inhibitors | |
| CA2498420A1 (en) | Lipophilic diesters of chelating agent for inhibition of enzyme activity | |
| JP2003508381A (ja) | 高脂血症の予防または治療用薬剤の製造のためのビススルホンアミドの使用 | |
| US20260069585A1 (en) | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES | |
| CN105979942A (zh) | 用于治疗或缓解疼痛的氨基磺酸酯衍生物 | |
| CN115003669B (zh) | 化合物及其用于治疗α1-抗胰蛋白酶缺乏症的用途 | |
| US12435025B2 (en) | Triphenylphosphonium-tethered salicylamine derivatives | |
| US11732007B2 (en) | Therapeutic compounds and methods | |
| JP6871919B2 (ja) | 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法 |